脂蛋白 (a) 和心肌梗塞:对长期死亡率的影响
Jian Zhang1, Lin Jia1, Yu Yang1
1Cardiology Department, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Lipids in health and disease
|June 9, 2023
概括
升高的脂蛋白 (a) [Lp(a) ]预测心肌梗塞 (MI) 患者的左心室喷射率 (LVEF) 降低. LVEF,而不是Lp (a) 水平,预测了MI后的长期死亡率.
科学领域:
- 心脏病学 心脏病学
- 临床生物化学 临床生物化学
- 心血管研究研究心血管研究
背景情况:
- 脂蛋白 (a) [Lp(a) ]是冠状动脉样硬化心脏病的已知危险因素.
- 在心肌梗塞 (MI) 患者中,Lp(a) 和左心室喷射率 (LVEF) 之间的关系尚不清楚.
- 调查这种相关性对于了解心脏病发作预后至关重要.
研究的目的:
- 检查心脏病发作患者的Lp (a) 水平和LVEF之间的相关性.
- 评估Lp (a) 对这一群体的长期死亡率的影响.
- 确定潜在的预测标志物,用于MI后的不良结果.
主要方法:
- 通过冠状动脉血管学诊断的436名MI患者的回顾性分析.
- 患者根据Lp (a) 度和LVEF (<50%降低,≥50%正常) 进行了分层.
- 统计方法评估了Lp,LVEF和死亡结果之间的相关性.
主要成果:
- 在Lp(a) 水平和LVEF之间发现了显著的负相关性 (r = -0.407,P < 0.001).
- 度> 455 mg/L被确定为降低LVEF的预测因素 (AUC: 0.7694,P < 0.0001).
- 虽然Lp(a) 没有预测临床终点,但LVEF预测了所有原因和心脏病死亡率.
结论:
- 升高的Lp (a) 与心脏病发作患者左心室喷射分数受损有关.
- LVEF是长期所有原因和心脏病死亡率MI后的显著预测因素.
- 这些发现凸显了LVEF在心脏病发作管理中的预后重要性.
相关概念视频
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
716
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
716
01:26Coronary Artery Disease IV: Preventive Measures
25
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
25
01:26Atherosclerosis III: Management
15
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
15
01:30Coronary Artery Disease I: Introduction
33
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
33
01:21Myocarditis I: Introduction
10
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
10
01:38Inflammation
54.0K
Overview
54.0K